Fibroblast growth factor receptor 3 (FGFR3) is the most common mutation in upper tract urothelial carcinoma (UTUC), found in 54% to 92% of diagnosed patients. A recent phase 1b trial by Surena F. Matin, MD, and colleagues analyzed the effects of the FGFR inhibitor infigratinib in localized UTUC. Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations. ...
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Dr. Moussa provides an overview of his research on prognostic factors of relapse in small cell neuroendocrine carcinomas.
The use of minimally invasive RNU is linked to improved median OS and 90-day mortality in octogenarian patients with UTUC.
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Advertisement
Roundtable Discussions
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Advertisement
Section Editor
Katie S. Murray, DO, MSUrologic Oncologist | NYU Langone Urology and Bellevue Hospital
Advertisement
Get the latest UTUC research straight to your inbox.
